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An acquired translocation in JAK2 Val617Phe-negative
essential thrombocythemia associated with autosomal
spread of X-inactivation
The classical myeloproliferative disorderscomprise polycythemia vera, essentialthrombocythemia and idiopathic
myelofibrosis, which share clinico-pathologi-
cal features including a tendency to leukemic
transformation.1 We and others have demon-
strated that the gain-of-function mutation
Val617Phe in the tyrosine kinase JAK2 is pres-
ent in most cases of polycythemia vera, but in
only half the cases of essential thrombo-
cythemia and idiopathic myelofibrosis, with
the pathogenesis of Val617Phe -negative cases
still obscure.2-5
The study of rare chromosomal transloca-
tions has hastened the identification of genes
normally targeted by sub-microscopic muta-
tions in inherited disorders6 and of oncogenes
relevant to hematologic malignancies.7 To
investigate the pathogenesis of
JAK2Val617Phe-negative myeloproliferative
disorders we studied a case of essential throm-
bocythemia carrying the translocation
t(X;5)(q13;q33),8 particularly as several docu-
mented translocations in myeloproliferative
disorders and other clonal myeloid disorders
involve band Xq13.9,10
Design and Methods
Samples
Blood and marrow were obtained with
informed consent and processed as described
elsewhere.11 The purity of granulocytes, T
cells, and platelets was >95%. DNA and RNA
were prepared using standard methods.12
Fluoresence in situ hybridization (FISH) and
chromosome G-banding
Metaphases were derived from bone mar-
row and from blood after phytohemagglutinin
(PHA) stimulation. Chromosomal G-banding
and FISH with human DNA clones were per-
formed as described previously.11
Chromosome walking
Chromosome microdissection and amplifi-
cation by degenerate oligonucleotide primer
(DOP)-polymerase chain reaction (PCR) has
been described elsewhwere.13 The DOP-PCR
product was used as the template for chromo-
some walking. For each sequence-tagged site
(STS), two rounds of PCR were performed
using the same primer pair with appropriate
controls. Primers and conditions are available
on request. 
Derivation and isolation of hematopoietic
cell colonies
Mononuclear cells were isolated from 20 mL
blood,11 suspended at 1 to 6×105 cells/mL in
MethocultGF H4534 medium (Stem Cell
Technologies) and incubated in 5% CO2. After
13-14 days individual colony-forming unit
granulocyte monocyte (CFU-GM) colonies
were lysed in Tri-reagent (Sigma) and stored at
–80°C until used. 
Reverse transcriptase (RT)-PCR, DNA-PCR
and rapid amplification of cDNA ends (RACE)
RT reactions were performed in a total vol-
ume of 20 µL using 1 µg of total RNA or the
entire RNA from a CFU-GM as described by
Li et al.14 The RT-PCR and DNA-PCR proce-
dures used were those reported by Bench et
al.11 The HDAC8 RT-PCR primers were
AGATGAAGCATCTGGTTTTT (P1) and
TGGGATCTCAGAGGATAGTG (P2). 5’ and
3’-RACE-ready cDNA were prepared accord-
From the Department of
Hematology, University of
Cambridge, UK (GSV, PC, JL, BH,
NF, EJB, LMS, ARG); Hutchison/MRC
Research Centre, Cambridge, UK
(IR); Department of Haematology,
Aberdeen Royal Infirmary, UK
(LRM, DAC).
Correspondence:
Professor Anthony R. Green,
Department of Haematology,
Cambridge Institute for Medical
Research, Hills Rd, Cambridge CB2
2XY, UK.
E-mail: arg1000@cam.ac.uk
The acquired mutation Val617Phe in the tyrosine kinase JAK2 was recently identified in
most but not all patients with classical myeloproliferative disorders. We describe a cytoge-
netic and molecular study of a JAK2Val617Phe-negative case of essential thrombo-
cythemia harboring the acquired translocation t(X;5)(q13;q33). We show that this involves
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cy and such a mechanism may underlie the pathogenesis of related disorders with translo-
cations involving Xq13.
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ing to the manufacturer’s instructions using the SMART
RACE II kit (Clontech). Primers and conditions are avail-
able on request.
Methylation-sensitive Southern blotting
Southern blotting was performed using standard meth-
ods12 with the probe generated by PCR (primers:
TGGTCTTTCATCCCGACTTC and ATCTGCCAAAC-
CCTTTTCCT).
Results and Discussion
A 47-year-old woman (EW) who presented in 1998
with localized breast carcinoma was found to have
thrombocytosis and to carry t(X;5)(q13;q33) in nine of ten
bone marrow metaphases. The salient features of this
case have been published8 and meet international diagnos-
tic criteria for essential thrombocythemia.15 The JAK2
Val617Phe mutation was not detected in marrow nucleat-
ed cells or blood granulocytes by allele-specific PCR and
BsaXI digestion.2 In 2002, the patient had a localized renal
tumor removed surgically. Chromosomal fragility studies
of blood lymphocytes were normal. In 2005, the patient
remains free of breast and renal cancer and is taking
hydroxyurea for her thrombocytosis. 
Using G-banding and FISH, t(X;5)(q13;q33) was identi-
fied in 58 of 60 bone marrow metaphases derived 4 years
after diagnosis, but not in 150 blood PHA-derived and 250
skin fibroblast metaphases, confirming that the transloca-
tion was acquired (data not shown). A trephine biopsy
revealed hypolobated megakaryocytes, a feature of 5q
minus syndrome (see online appendix). FISH with human
DNA clones localised the chromosome 5 breakpoint to
BAC RP11-426L22 (AC008491) and the chromosome X
breakpoint to BAC CEPHB328P12 (AL133500) (see online
appendix). To define the breakpoints molecularly, a single
derivative chromosome 5 (der5) was microdissected
(Figures 1A and 1B) and amplified by DOP-PCR. Correct
microdissection was confirmed by back-hybridizing
labeled DOP-PCR product onto a normal metaphases
(Figure 1C). The breakpoint region was narrowed using
chromosome walking (Figures 1D and 1E) and the break-
point cloned from granulocyte DNA by long-range PCR:
chromosome 5 sequences finished at nucleotide 21515 of
AC008491 and chromosome X sequences started at
nucleotide 138072 of AL133500. PCR across the derX
breakpoint gave a product of the expected size, confirm-
ing a reciprocal translocation without large deletions adja-
cent to the breakpoint (data not shown). 
The map of der5 in Figure 2A highlights two signifi-
cant consequences of the t(X;5)(q13;q33): (i) the HDAC8
gene  is physically disrupted and (ii) the common delet-
ed region (CDR) for 5q minus syndrome lies within 6 Mb
of the X-inactivation center (XIC). 5’ and 3’ RACE on mar-
row and blood cDNA led to isolation of full length
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Figure 1. Molecular mapping of the t(X;5)
(q13;q33) breakpoint. A. Phase-contrast image of
FISH with whole chromosome X paint highlights
the normal X, derX and der5 chromosomes in a
t(X;5)(q13;q33)-carrying metaphase (arrowheads).
(B) Same metaphase as (A) after microdissection
of the der5 (arrow). (C) Reverse FISH of labeled
microdissected material from (b) against a normal
male metaphase shows hybridization to chromo-
some 5 (except its distal long arm) and the long
arm of chromosome X, as expected for der5. (D)
Examples of chromosome walking by sequence-
tagged-site PCR (STS-PCR). For each STS-PCR
experiment the four lanes represent i) first round
PCR (DOP-PCR product as template), ii) second
round PCR, iii) genomic DNA PCR (positive control)
and 4) water (negative control). The location of the
STS on the corresponding BAC/GenBank
sequence is indicated in kilobases (kb). Lanes 1-4
and 5-8 show positive results (STS present within
microdissected material). Lanes 9-12 and 13-16
show negative results (STS absent from microdis-
sected material). Note that negative control lanes
commonly showed non-specific short PCR prod-
ucts, presumed to represent primer multimers
resulting from serial amplifications with the same
primer pair. (E). Summary of chromosome walking
by STS-PCR around the breakpoint regions of chro-
mosome X (AL133500) and chromosome 5
(AC00849). The breakpoint locations were nar-
rowed to regions of 15 kb on chromosome X and
2 kb on chromosome 5 (arrows), thus enabling
long-range PCR across the der5 breakpoint. The
presence of presumed false negative results
(marked *), including the example† in lanes 9-12
in (D), are in keeping with the anticipated incom-
plete amplification of microdissected DNA by DOP-
PCR. 
HDAC8 and a splice variant (GenBank, BE792074), but
no fusion or abnormal HDAC8 transcripts (data not
shown). PHKA1 and RPS4X, two genes that flank
HDAC8, are discordant with regards to X-inactivation in
humans,16 but the status of HDAC8 has not previously
been determined. We show, using methylation-sensitive
genomic Southern blotting, that HDAC8 is subject to X-
inactivation (Figure 2B and 2C). 
To examine whether the active (Xa) or inactive (Xi) X
chromosome is involved in t(X;5)(q13;q33), we studied
HDAC8 mRNA expression in individual translocation-car-
rying (verified by PCR) CFU-GM colonies. Using HDAC8
RT-PCR primers on opposite sites of the chromosome 5
breakpoint, HDAC8 mRNA was amplified from all
colonies tested (Figure 2D), demonstrating that its intact
(non-translocated) allele is transcriptionally active. This sug-
gests that either Xi is involved in the translocation or that
Xa is involved with subsequent reactivation of HDAC8i on
Xi. To distinguish these possibilities, we studied an
expressed polymorphism (C/T) in the iduronate-2-sul-
phatase gene (IDS) (dbSNP: 1141608), located on the dis-
tal long arm of chromosome X and thus on der5. We show
that der5 carries the C allele, whilst only the T allele is
expressed in 12 of 12 t(X;5)(q13;q33)-carrying CFU-GM
(Figure 2D). This demonstrates that der5 carries a tran-
scriptionally silent IDSi allele and therefore that Xi is
involved in the translocation. 
Since the t(X;5)(q13;q33) places the 5q minus CDR
within 6 Mb of the XIC and given the presence of histolog-
ical features of this syndrome in the marrow of our
patient, we speculated that X-inactivation spread to auto-
somal genes in this CDR. We therefore studied expression
of informative/polymorphic genes in the region of the
CDR in individual, translocation-carrying, CFU-GM
colonies. The woman was heterozygous for expressed
polymorphisms in four genes: TCOF1, HSPA9B, G3BP
and GM2A (Figure 3A). TCOF1 and HSPA9B were
expressed biallelically in CFU-GM (data not shown). By
contrast, G3BP and GM2A showed monoallelic silencing
((Figure 3B). In the case of G3BP, we show that the silent
allele was carried on der5. These data are consistent with
silencing of chromosome 5 genes by patchy spread of X-
inactivation as described in reports of inherited X-auto-
some translocations.17
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Figure 2. The inactive X-chromosome is involved in
t(X;5)(q13;q33). (A) Map of the breakpoint region on
the derivative chromosome 5 (Der5): HDAC8 is phys-
ically disrupted on chromosome X and the 5q minus
CDR (5q-) comes to lie 6 Mb from the X-inactivation
centre (XIC). The chromosome 5 breakpoint is located
in intergenic DNA and does not directly disrupt the
intron-exon structure of any known or predicted gene.
Arrows indicate the direction of gene transcription.
(B) Design of methylation-sensitive genomic Southern
blot for HDAC8: DraI (D) digestion generates an 1.8
kb restriction fragment containing the HDAC8 exon 1
and the associated CpG island (shaded box). The
methylation-sensitive AvaI (A*), cleaves this into two
fragments (1.2 kb and 0.6 kb) when the HDAC8 CpG
island is unmethylated but leaves the 1.8 kb frag-
ment intact when the CpG island is methylated. The
1.8 kb and 1.2 kb fragments can be detected by
Southern hybridization with the same DNA probe (p).
(C) Southern hybridization shows complete AvaI
digestion at the HDAC8 CpG island of leukocyte DNA
from normal males (lanes 1-3) (only the 1.2 kb frag-
ment seen) but incomplete digestion of that from nor-
mal females (lanes 4-6) (1.8 kb and 1.2 kb frag-
ments), even when a smaller quantity of DNA was
used (lane 4). Thus, females carry both methylated
and unmethylated copies of the CpG island associat-
ed with the gene’s promoter, whereas males carry
only an unmethylated allele, demonstrating that
HDAC8 is subject to X-inactivation in females. (D)
Four examples of individual CFU-GM colonies carrying
t(X;5)(q13;q33) (verified by PCR amplification across
the der5 breakpoint, data not shown), were studied
for HDAC8 mRNA expression by RT-PCR using primers
from exons lying on opposite sites of the X-chromo-
some breakpoint (P1 on exon 9 and P2 on exon 11).
The gene for β2-microglobulin (β2M) was used as a
positive control. All four colonies expressed intact
HDAC8 mRNA. (E) IDS is located on the distal long
arm of the normal X-chromosome and is therefore
present on der5 (see Figure 2A). PCR and RT-PCR, fol-
lowed by direct sequencing were used to identify the
IDS allele present. Both C and T alleles were ampli-
fied from genomic DNA (gDNA), confirming that our
patient is heterozygous for this polymorphism
(dbSNP: 1141608). The allele amplified from the
microdissected der 5 and therefore present on the X-
chromosome involved in t(X;5)(q13;q33) is the C
allele. All 12 individual t(X;5)(q13;q33)-carrying CFU-
GM (example shown), expressed the mRNA from the
T allele, confirming that the inactive X chromosome is
involved in the translocation. 
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We report the first case of a somatic clonal translocation
involving Xi associated with persistent silencing of auto-
somal genes. Spread of X-inactivation up to 45 Mb away
from an X-autosome junction has been described in inher-
ited X-autosome translocations.17 Such translocations are
established prior to initiation of X-inactivation and auto-
somal genes are thought to be silenced by an otherwise
physiological process extending beyond the X-autosome
junction. By contrast in somatic cells X-inactivation is
thought to be transcriptionally stable and persists even
when the XIC is removed18 and although autosomal X-
inactivation has been induced experimentally in somatic
cell lines by inserting XIST transgenes into autosome,19 it
was progressively lost in culture. In the case described
here, epigenetic silencing of genes was present several
years after the translocation arose suggesting it was
advantageous.
Juxtaposition of the XIC next to the 5q minus CDR and
the presence of histological features of this syndrome
raised the possibility that silencing of autosomal genes
through spread of X-inactivation contributed to our
patient’s clonal disorder. In keeping with this, we have
shown that genes in the CDR are silenced. It is notewor-
thy that the CDR genes studied were picked solely
because they were informative in our patient. This makes
a field effect (i.e. spread of X-inactivation) more likely to
be operative than disruption of gene-specific regulatory
elements by the translocation as has been described for
translocations between autosomes.20
Spread of X-inactivation may not be unique to this case
as there are several reports of patients with clonal myeloid
disorders carrying chromosomal translocations between
Xq13 and autosomal regions such as 5q33 and 20q13 that
are recurrently deleted in clonal myeloid disorders.9,10,21,22
Furthermore, a search of the Mitelman Database
(http://cgap.nci.nih.gov/Chromosomes/Mitelman) for clonal
bone marrow disorders carrying t(X;5) or t(X;20) identi-
fied 24 cases, all in females, suggesting a requirement for
the presence of Xi. Our data support a novel mechanism
of leukemogenesis, namely the epigenetic silencing of
autosomal genes as a result of spread of X-inactivation in
Xi - autosome translocations. 
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Figure 3. Evidence for autosomal spread of
X-inactivation. (A) Map of the der5 break-
point region showing the distance of the
genes G3BP, GM2A, TCOF1 and HSPA9B
from the X-inactivation center (XIC). The
patient was found to be heterozygous for
expressed polymorphisms in these genes
after screening for several known polymor-
phisms in the region. (B) Both alleles of
GM2A and G3BP (C/T) were amplified from
the patient’s genomic DNA (gDNA) while her
CFU-GM colonies expressed only one of the
two alleles by RT-PCR (G3BP-C and GM2A-T).
For G3BP we were able to amplify the allele
carried by der5 (Der 5 DNA) and type it as
the T allele. This was not possible for GM2A,
presumably as a result of incomplete ampli-
fication of der5 by DOP-PCR as was seen for
some STSs used for chromosome walking.
(Figure 1E) TCOF1 and HSPA9B were
expressed biallelically (data not shown).
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